MHLW Japan Approves Additional Indications For Soliris, NESP and Samusca
This article was originally published in PharmAsia News
Japan’s Ministry of Health, Labor and Welfare approved additional indications for three drugs on Sept. 13.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.